Maria D. Lozano

In the 21st century, there has been a dramatic shift in the diagnosis and management of non‐small cell lung carcinoma (NSCLC), with an increasing use of minimally invasive tissue acquisition methods. Current treatments require morphologic subtyping and biomarker information in all cases. Determining such biomarkers is a continuously evolving field; current guidelines state that the determination of mutations on the Epidermal Growth Factor ( EFGR ), Kirsten Rat Sarcoma viral oncogene homolog ( KRAS ), Proto‐oncogene B‐Raf ( BRAF ), Human epidermal growth factor receptor 2 ( HER2 ) and Anaplastic Lymphoma Kinase ( ALK ), genes as well as fusions on genes such as ROS Proto‐Oncogene 1, Receptor Tyrosine Kinase ( ROS1 ), MET proto‐oncogene, receptor tyrosine kinase ( MET ), RET proto‐oncogene ( RET ), and the Neurotrophic Tyrosine Receptor Kinase ( NTRK ) family is mandatory. While analyzing such alterations, some of them were first reported to be mutually exclusive, although in recent years, it has been shown otherwise in some of these cases. Moreover, so was the case with the concomitant expression of NTRK fusions and EGFR mutations. We present a case report of a patient with concomitant EGFR mutation and NTRK1 fusion.